Bio-Techne (TECH)
NASDAQ:TECH
Top Page
Bio-Techne
(NASDAQ:TECH)
Select Model
Select Model
Rating:65Neutral
Price Target:
$57.00
▲(8.16% Upside)
Action:ReiteratedDate:02/05/26
Overall score reflects pressured recent operating performance (declining TTM revenue and margin compression) partly offset by a strong balance sheet and positive cash generation. Technicals are supportive with the stock trending above key moving averages, but valuation is a major drag given the very high P/E and low yield. Earnings call guidance suggests timing-related headwinds should ease with continued margin improvement, supporting a mid-range score.
Positive Factors
High gross margin profile
Sustained ~65%+ gross margins indicate structural pricing power and high-margin consumable mix. This margin base supports investment in R&D, absorbs temporary mix shifts, and enables durable profitability leverage as instrument installed base and recurring reagent sales scale over the next several quarters.
Negative Factors
Declining TTM revenue and compressed profitability
A near-10% TTM revenue decline alongside a sharp fall in net margin to ~6.7% from much higher prior levels reflects meaningful demand pressure and margin squeeze. These trends reduce operating leverage and cash-flow growth potential until underlying end-market demand and mix recover.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin profile
Sustained ~65%+ gross margins indicate structural pricing power and high-margin consumable mix. This margin base supports investment in R&D, absorbs temporary mix shifts, and enables durable profitability leverage as instrument installed base and recurring reagent sales scale over the next several quarters.
Read all positive factors
Bio-Techne (TECH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.25B
Dividend Yield0.54%
Average Volume (3M)2.42M
Price to Earnings (P/E)60.3
Beta (1Y)1.03
Revenue Growth3.85%
EPS Growth-48.17%
CountryUS
Employees3,100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.46
Shares Outstanding156,453,300
10 Day Avg. Volume2,468,124
30 Day Avg. Volume2,417,922
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)4.22
Price to Sales (P/S)6.64
P/FCF Ratio31.59
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue6.93
Enterprise Value/Gross Profit10.63
Enterprise Value/Ebitda37.07
Forecast
1Y Price Target
$74.00Price Target Upside40.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)1.98
Revenue Forecast (FY)$1.22B
Bio-Techne Business Overview & Revenue Model
Company Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Prote...
How the Company Makes Money
Bio-Techne primarily makes money by selling life science research and clinical research tools to customers such as academic and government laboratories, biotechnology and pharmaceutical companies, and clinical/diagnostic developers. Revenue is gen...
Bio-Techne Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyBio-Techne Earnings Call Summary
Earnings Call Date:Feb 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call balanced encouraging execution and strategic progress against clear near-term headwinds. Positive drivers include 10% adjusted EPS growth, ~100 bps operating margin expansion, strong instrument bookings (Comet, LEO), product innovation (Ella assays), geographic momentum in China and APAC, Wilson Wolf growth, and solid cash generation and balance-sheet metrics. Offsetting these positives were flat consolidated revenue, material short‑term order timing impacts from two large cell therapy customers (causing steep GMP reagent declines), gross margin compression from unfavorable product/customer mix, and continued weakness in emerging biotech and parts of academia. Management expects the cell therapy timing headwinds to moderate through Q4 and underlying business trends to improve, supporting a constructive medium-term outlook.Positive Updates
Adjusted EPS Growth
Adjusted EPS of $0.46, up 10% year-over-year (foreign exchange contributed ~$0.04 of the beat). GAAP EPS was $0.24, up from $0.22 in the prior year period.
Negative Updates
Flat Overall Revenue and Organic Growth
Total revenue of $295.9M was flat year-over-year and organic growth was flat for the quarter, reflecting order timing and soft pockets in biotech and academia.
Read all updates
Q2-2026 Updates
Positive
Negative
Adjusted EPS Growth
Adjusted EPS of $0.46, up 10% year-over-year (foreign exchange contributed ~$0.04 of the beat). GAAP EPS was $0.24, up from $0.22 in the prior year period.
Read all positive updates
Company Guidance
Bio-Techne guided that Q3 organic growth should be roughly consistent with Q2 (Q2 revenue $295.9M, flat year‑over‑year) but flagged a ~300 basis‑point headwind in Q3 from timing at two large cell‑therapy customers (and an additional ~100 bps OEM timing headwind), with that cell‑therapy drag moderating to roughly 100–200 bps in Q4 and fully lapping out in fiscal 2027; excluding those customer‑specific and OEM timing effects management expects underlying growth in the mid‑single digits (Q1 ex‑items 1%, Q2 ex‑items 3%), and reaching the company’s full‑year low single‑digit view would require mid‑single‑digit growth in Q4. From a margin standpoint they remain on track to expand adjusted operating margin by ~100 bps for the full year (Q2 adjusted operating margin 31.1%, up 100 bps), expecting back‑half margin expansion driven roughly half by gross‑margin mix improvement and half by higher revenue; management also reiterated confidence in improving biotech funding, continued China/APAC momentum, and the balance sheet (cash $172.9M, bank debt $260M, leverage well under 1x EBITDA) to support M&A.Bio-Techne Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.22B | 1.22B | 1.16B | 1.14B | 1.11B | 931.03M |
| Gross Profit | 792.76M | 790.27M | 769.73M | 769.82M | 756.50M | 632.85M |
| EBITDA | 227.21M | 216.88M | 313.14M | 457.11M | 413.76M | 249.87M |
| Net Income | 81.10M | 73.40M | 168.10M | 285.26M | 272.05M | 140.41M |
Balance Sheet | ||||||
| Total Assets | 2.52B | 2.56B | 2.70B | 2.64B | 2.29B | 2.26B |
| Cash, Cash Equivalents and Short-Term Investments | 172.88M | 162.19M | 152.86M | 204.31M | 247.03M | 231.55M |
| Total Debt | 350.89M | 444.06M | 419.54M | 454.96M | 325.97M | 420.55M |
| Total Liabilities | 511.71M | 639.06M | 635.02M | 672.18M | 593.79M | 691.72M |
| Stockholders Equity | 2.01B | 1.92B | 2.07B | 1.97B | 1.70B | 1.56B |
Cash Flow | ||||||
| Free Cash Flow | 223.02M | 256.55M | 236.10M | 216.15M | 280.36M | 307.86M |
| Operating Cash Flow | 249.32M | 287.56M | 298.98M | 254.39M | 325.27M | 352.16M |
| Investing Cash Flow | -13.78M | -35.18M | -203.03M | -265.65M | -96.85M | -243.52M |
| Financing Cash Flow | -251.69M | -253.91M | -122.40M | 22.62M | -242.85M | -62.55M |
Bio-Techne Technical Analysis
Negative
52.70
Price Trends
59.76
Negative
60.28
Negative
57.56
Negative
Market Momentum
-2.03
Negative
42.28
Neutral
79.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Negative. The current price of 52.7 is below the 20-day moving average (MA) of 53.43, below the 50-day MA of 59.76, and below the 200-day MA of 57.56, indicating a bearish trend. The MACD of -2.03 indicates Negative momentum. The RSI at 42.28 is Neutral, neither overbought nor oversold. The STOCH value of 79.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECH.
Bio-Techne Risk Analysis
Bio-Techne disclosed 27 risk factors in its most recent earnings report. Bio-Techne reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio-Techne Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $7.47B | 25.45 | 92.67% | ― | 31.19% | 59.01% | |
70 Outperform | $4.10B | 36.27 | 15.25% | ― | 17.92% | -26.13% | |
69 Neutral | $11.64B | 12.74 | -8.82% | ― | 4.14% | -179.96% | |
69 Neutral | $19.57B | -14.22 | -18.32% | ― | -83.82% | -109.22% | |
65 Neutral | $8.25B | 60.28 | 4.10% | 0.54% | 3.85% | -48.17% | |
52 Neutral | $5.59B | -35.39 | -179.05% | ― | 54.92% | 28.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
TECH
Bio-Techne
52.70
-6.90
-11.58%
CORT
Corcept Therapeutics
38.53
-18.15
-32.02%
HALO
Halozyme
63.29
-1.19
-1.85%
JAZZ
Jazz Pharmaceuticals
189.15
62.75
49.64%
RYTM
Rhythm Pharmaceuticals
81.90
28.41
53.11%
ROIV
Roivant Sciences
27.35
16.87
160.97%
Bio-Techne Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Bio-Techne Names New Diagnostics and Spatial Biology President
Neutral
Feb 11, 2026
Bio-Techne Corporation announced on February 11, 2026, that Dr. Matt McManus will transition from his role as President of the Diagnostics and Spatial Biology Segment effective March 1, 2026, after helping optimize the organization, including lead...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Bio-Techne posts stable Q2 results with margin gains
Positive
Feb 4, 2026
On February 4, 2026, Bio-Techne reported second-quarter fiscal 2026 results for the period ended December 31, 2025, with revenue flat year-on-year at $295.9 million but improvements in profitability driven by cost controls and portfolio optimizati...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.